ADMA Biologics Upcoming PDUFA Dates and Milestones
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ADMA Biologics, Inc. (ADMA), a biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases.
The company is progressing towards the commercialization stage. ADMA improved the U.S. Food and Drug Administration compliance status for its manufacturing facility in Boca Raton, Florida, which allowed it to submit applications for approval for the relaunch of BIVIGAM® and the approval and launch of RI-002.
ADMA pipeline and PDUFA dates, including analysts review and target in this full report READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/adma-biologics/
The company also obtained FDA approval for its third plasma collection center, which was announced during the third quarter and occurred ahead of expectations. The management is looking forward to the coming months as it continues working with the FDA and commercializes its intravenous immune globulin products, which are expected to grow the top line in 2019.
ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its product candidate, RI-002.
Pipeline review, the company's upcoming milestones and more in this original and comprehensive full report READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/adma-biologics/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
